** Shares of Orthocell OCC rise as much as 6.5% to A$1.395
** Regenerative medicine co to boost Marine Biomedical stake to 12% from 1.7% for A$1 mln ($650,600)
** Investment contingent upon OCC securing exclusive first right of refusal in relation to distribution rights of PearlBone
** PearlBone is Marine Biomedical’s bone substitute product with potential applications in bone repair and regeneration
** YTD, OCC shares up 0.4%
($1 = 1.5370 Australian dollars)
